Safety of rituximab in the treatment of B cell malignancies: implications for rheumatoid arthritis

The chimeric anti-CD20 monoclonal antibody rituximab has been used extensively in the treatment of B cell malignancies, and more recently it has emerged as a potential treatment for rheumatoid arthritis (RA), via selective B lymphocyte depletion. Experience in oncology shows that rituximab is well t...

Descripción completa

Detalles Bibliográficos
Autor principal: Hainsworth, John D
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2003
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2833440/
https://www.ncbi.nlm.nih.gov/pubmed/15180892
http://dx.doi.org/10.1186/ar1008

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2833440/
https://www.ncbi.nlm.nih.gov/pubmed/15180892
http://dx.doi.org/10.1186/ar1008

Ejemplares similares